Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
13 studies found for:    "BMS-708163"
Show Display Options
RSS Create an RSS feed from your search for:
"BMS-708163"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Study to Evaluate the Safety, Pharmacokinetics and Tolerability of BMS-708163
Condition: Alzheimer's Disease
Interventions: Drug: BMS-708163 (Gamma-Secretase Inhibitor);   Drug: Placebo matching BMS-708163
2 Completed Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163
Condition: Alzheimer's Disease
Interventions: Drug: BMS-708163;   Drug: Placebo
3 Completed Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole
Condition: Alzheimer Disease
Interventions: Drug: BMS-708163;   Drug: BMS-708163 + Ketoconazole;   Drug: Ketoconazole;   Drug: Fluconazole;   Drug: BMS-708163 + Fluconazole
4 Terminated A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Avagacestat;   Drug: Placebo
5 Completed A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: BMS-708163;   Drug: Placebo
6 Completed Safety Study of Multiple-dose of Gamma-secretase Inhibitor in Healthy Male Japanese and Healthy Elderly Japanese
Condition: Healthy
Interventions: Drug: BMS-708163;   Drug: Placebo
7 Completed Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER)
Condition: Alzheimer Disease
Interventions: Drug: galantamine;   Drug: BMS-708163
8 Completed Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy Subjects
Condition: Alzheimer Disease
Interventions: Drug: BMS-708163;   Drug: Placebo;   Drug: Moxifloxacin
9 Completed Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's Disease
Conditions: Alzheimer's Disease;   Healthy
Intervention: Drug: BMS-708163
10 Completed Drug Interaction Study With a Potential Alzheimer's Disease Compound
Condition: Alzheimer Disease
Interventions: Drug: Interacting drugs - Cooperstown Cocktail (midazolam, warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan);   Drug: BMS-708163;   Drug: BMS-708163 + Cooperstown Cocktail
11 Completed Drug-Drug Interaction Study With Rifampin
Condition: Alzheimer Disease
Interventions: Drug: BMS-708163;   Drug: Rifampin
12 Completed Multiple Dose Japanese Bridging Study
Condition: Alzheimer Disease
Interventions: Drug: BMS-708163;   Drug: Placebo
13 Completed Drug-Drug Interaction Study With Aricept® (Donepezil)
Condition: Alzheimer Disease
Interventions: Drug: Donepezil;   Drug: BMS-708163

Indicates status has not been verified in more than two years